Alnylam Pharmaceuticals
ALNY
435 hedge funds and large institutions have $19B invested in Alnylam Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 157 increasing their positions, 132 reducing their positions, and 40 closing their positions.
90% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 40
33% more call options, than puts
Call options by funds: $252M | Put options by funds: $189M
19% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 132
7% more funds holding
Funds holding: 405 → 435 (+30)
0.24% less ownership
Funds ownership: 93.95% → 93.71% (-0.24%)
10% less capital invested
Capital invested by funds: $21.1B → $19B (-$2.08B)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$123M |
| 2 |
JP Morgan Chase
New York
|
+$97.8M |
| 3 |
Janus Henderson Group
London,
|
+$89.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$69.8M |
| 5 |
RI
RTW Investments
New York
|
+$54.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$232M |
| 2 |
Morgan Stanley
New York
|
-$152M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$97.9M |
| 4 |
Alkeon Capital Management
New York
|
-$73.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$44.2M |
ALNY Hedge Fund Activity: Q4 2021 in Review
435 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2021, worth a combined $19B — down 9.9% from $21.1B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new ALNY positions and 40 closed out — a net gain of 36 holders — while 157 added to existing stakes and 132 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was BlackRock, cutting an estimated $232M.
- 435 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2021, up from 405 in Q3 2021.
- Funds reported $19B of Alnylam Pharmaceuticals stock for Q4 2021, down 9.9% quarter-over-quarter.
- 76 funds opened new Alnylam Pharmaceuticals positions in Q4 2021 and 40 closed out, a net change of +36 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2021 was T. Rowe Price Associates, an estimated $123M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2021 was BlackRock, an estimated $232M sold.
Based on aggregated 13F filings for Q4 2021.